Flash Finance

Alivus Life Sciences LimitedALIVUSCorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹1,309.50
MCap ₹16,077 Cr · P/E 26.7
Alivus Life Sciences Limited — Stock analysis & AI research Alivus Life Sciences Limited — Multibagger AI analysis Alivus Life Sciences Limited — Seasonality — best & worst months Alivus Life Sciences Limited — Technical indicators & charts Alivus Life Sciences Limited — Technical setup — score, trend, support & resistance Alivus Life Sciences Limited — Bull Flag pattern forming Alivus Life Sciences Limited — Live exchange announcements
📋 High ROCE Stocks📋 High Operating Margin Stocks📋 High Interest Coverage Stocks📋 Low Debt Stocks📋 High Promoter Holding Stocks📋 Small Cap Stocks List 📈 Bollinger Squeeze Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹640 Cr
Sales · Jun 2026
+6.4% YoY
₹212 Cr
Operating Profit · Jun 2026
+23.1% YoY
33.1%
OPM % · Jun 2026
+15.7% YoY
₹160 Cr
Net Profit · Jun 2026
+31.2% YoY
₹13.04
EPS · Jun 2026
+31.6% YoY

📝 Alivus Life Sciences Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Alivus Life Sciences Limited reported revenue of ₹640 crore for the quarter ended June 2026 (Q1 FY27), up 6.4% from ₹602 crore in the same quarter last year, and down 7.1% sequentially over the March 2026 quarter.

Net profit rose 31.2% year-on-year to ₹160 crore, from ₹122 crore. Earnings per share (EPS) came in at ₹13.04.

Operating profit stood at ₹212 crore — an operating margin (OPM) of 33.1%, compared with 28.6% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Alivus Life Sciences Limited posted revenue of ₹2,552 crore, a growth of 6.9% over FY25, with a net profit of ₹565 crore (up 16.5% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹2,590 crore with a net profit of ₹603 crore.

Valuation snapshot

At the current price of ₹1,309.50, ALIVUS has a market capitalisation of ₹16,077 crore and a trailing P/E of about 26.7.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 25th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 74.85%, foreign institutional investors (FIIs) 5.93%, domestic institutional investors (DIIs) 7.03%, public shareholders 12.19% of Alivus Life Sciences Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹16,077 Cr
Current Price ?
₹1,309.5
P/E ?
26.66below ind
Industry P/E ?
35.00
P/B ?
4.82
P/S ?
6.21
P/FCF ?
62.07
Enterprise Value ?
₹16,134 Cr
EV/EBITDA ?
19.28
PEG ?
3.33
Earnings Yield ?
4.7%
Dividend Yield ?
0.38%
Profitability & Returns
Sales (TTM) ?
₹2,590 Cr
OPM ?
32.3%
Profit after tax (TTM) ?
₹603 Cr
EPS (TTM) ?
₹49.12
ROCE ?
25.0%
ROE ?
18.1%
ROA ?
15.1%
Growth
Sales — latest qtr ?
₹640 Cr
PAT — latest qtr ?
₹160 Cr
YoY qtr sales growth ?
6.4%
YoY qtr profit growth ?
31.2%
Sales growth (3y) ?
6%
Sales growth (5y) ?
6%
Profit growth (3y) ?
8%
Profit growth (5y) ?
11%
Financial Health
Debt ?
₹57 Cr
Debt to Equity ?
0.02
Interest Coverage ?
180.5
Current Ratio ?
N/A
Ownership
Promoter holding ?
74.85%
Change in promoter holding ?
-0.09%
Pledged percentage ?
N/A
Market
Return 3 months ?
15.5%
Return 6 months ?
22.4%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 621578595573537589507642650602588673689640 +6.4% -7.1%
Operating Profit 206193167173141159134190198172179231215212 +23.1% -1.5%
Other Income 32523591010915-122322 +148.9% -2.6%
Interest 00000000111111 +30.7% +30.7%
Depreciation 1213131315141515161718202021 +21.1% +2.9%
Profit Before Tax 198182159161130150127185191163174198216212 +30.2% -1.7%
Net Profit 1461351191199811195137142122130150163160 +31.2% -1.8%
EPS 11.9511.059.699.697.999.107.7811.1811.589.9110.6012.2513.2513.04 +31.6% -1.6%
OPM % 33.2% 33.4% 28.1% 30.2% 26.3% 27.0% 26.4% 29.6% 30.5% 28.6% 30.4% 34.3% 31.2% 33.1% +15.7% +6.1%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹2,388 Cr ₹2,552 Cr ₹2,590 Cr +6.9%
Operating Profit ₹681 Cr ₹797 Cr ₹837 Cr +17.0%
OPM % 28.52% 31.23% 32.30% +9.5%
NPM % 20.31% 22.14% 23.28% +9.0%
Other Income ₹34 Cr ₹35 Cr ₹48 Cr +2.9%
Depreciation ₹60 Cr ₹75 Cr ₹79 Cr +25.0%
Interest ₹1 Cr ₹4 Cr ₹4 Cr +300.0%
EBIT ₹621 Cr ₹722 Cr ₹758 Cr +16.3%
PBT ₹653 Cr ₹751 Cr ₹800 Cr +15.0%
Tax — — ₹52 Cr —
Net Profit ₹485 Cr ₹565 Cr ₹603 Cr +16.5%
EPS ₹39.64 ₹46.01 ₹49.14 +16.1%
Material Cost — — ₹253 Cr —
Employee Cost — — ₹68 Cr —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 25252525 +0.0%
Reserves 2,1142,3082,7933,308 +18.4%
Borrowings 19175757 +0.0%
Other Liabilities 545501537594 +10.6%
Total Liabilities 2,7022,8503,4113,983 +16.8%
Fixed Assets 7818059551,048 +9.7%
CWIP 62106102273 +167.6%
Investments 00478780 +63.2%
Other Assets 1,8601,9391,8771,881 +0.2%
Total Assets 2,7022,8503,4113,983 +16.8%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
CFO/OP 71%85%81%93% +14.8%
Cash from Operating Activity 306414392565 +44.1%
Cash from Investing Activity -147-116-616-570 +7.5%
Cash from Financing Activity -388-279-6-64 -966.7%
Net Cash Flow -22818-230-69 +70.0%
Free Cash Flow 143285226259 +14.6%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 136122148153 +3.4%
Inventory Days 224251237237 +0.0%
Days Payable 158139137127 -7.3%
Cash Conversion Cycle 202235248263 +6.0%
Working Capital Days 176188201306 +52.2%
ROCE % 30%28%25%25% +0.0%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 74.94%74.91%74.91%74.87%74.85% -0.0%
FIIs 6.42%6.84%5.08%5.30%5.93% +11.9%
DIIs 5.62%5.47%7.13%7.27%7.03% -3.3%
Public 13.03%12.79%12.89%12.55%12.19% -2.9%
No. of Shareholders 1,38,5001,35,6431,32,7481,27,9691,22,777 -4.1%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ALIVUS Alivus Life ₹1,322.70 16,239 26.9 2,590 603 32.3% 23.3% 6.9% 16.5% 6.4% 31.2%
❓ Frequently asked questions
What was Alivus Life Sciences Limited's revenue in Q1 FY27?
Alivus Life Sciences Limited reported revenue of ₹640 crore for the quarter ended June 2026 (Q1 FY27), up 6.4% from ₹602 crore in the same quarter last year, and down 7.1% sequentially over the March 2026 quarter.
What was Alivus Life Sciences Limited's net profit in Q1 FY27?
Net profit rose 31.2% year-on-year to ₹160 crore, from ₹122 crore. Earnings per share (EPS) came in at ₹13.04.
What is ALIVUS's market capitalisation and P/E ratio?
At the current price of ₹1,309.50, ALIVUS has a market capitalisation of ₹16,077 crore and a trailing P/E of about 26.7.
Who owns Alivus Life Sciences Limited? (shareholding pattern)
As of Sep 2026, promoters held 74.85%, foreign institutional investors (FIIs) 5.93%, domestic institutional investors (DIIs) 7.03%, public shareholders 12.19% of Alivus Life Sciences Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI